Managing the patient with dementia in long-term care

Clinics in Geriatric Medicine

Volumn 27, Issue 2, 2011, Pages 135-152

  Rhodes Kropf, Jennifer ^a   Cheng, Huai ^b   Castillo, Elizabeth Herskovits ^c,d,e   Fulton, Ana Tuya ^f  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Geriatric Medicine Program   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e Givens Estates (CCRC)   (United States)

^f BROWN UNIVERSITY   (United States)

Author keywords

Agitation; Cholinesterase inhibitors; Dementia; Depression; Eating problems; Environment; Function; Memantine

Indexed keywords

CARBAMAZEPINE; CHOLINESTERASE INHIBITOR; DIPHENHYDRAMINE; DONEPEZIL; GALANTAMINE; HALOPERIDOL; MEMANTINE; OLANZAPINE; OXAZEPAM; PLACEBO; RIVASTIGMINE; SERTRALINE; TACRINE; TIOTIXENE; VALPROATE SEMISODIUM;

AGITATION; ALZHEIMER DISEASE; ANOREXIA; AROMATHERAPY; BRAIN FUNCTION; CHOLINERGIC TRANSMISSION; COGNITION; DAILY LIFE ACTIVITY; DEMENTIA; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; EATING DISORDER; EXERCISE; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER TOXICITY; LONG TERM CARE; MILD COGNITIVE IMPAIRMENT; NAUSEA; NEUROPROTECTION; PHOTOTHERAPY; QUALITY OF LIFE; REVIEW; SYNCOPE; VOMITING;

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; CHOLINESTERASE INHIBITORS; DEMENTIA; DEPRESSION; FEMALE; HUMANS; LONG-TERM CARE; MALE; MEMANTINE; PSYCHOMOTOR AGITATION; QUALITY OF LIFE; RESIDENTIAL FACILITIES; SOCIAL ENVIRONMENT;

EID: 79957919228     PISSN: 07490690     EISSN: 18798853     Source Type: Journal    
DOI: 10.1016/j.cger.2011.01.001     Document Type: Review

References (106)

1. Watkins P.B., Zimmerman H.J., Knapp M.J., et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994, 271:992. [see comments].
2. Novartis Exelon labeling update reflects report of esophageal rupture. The Pink Sheet 2001, 63:24.
3. Weyer G., Erzigkeit H., Kanowski S., et al. Alzheimer's disease assessment scale: reliability and validity in a multicenter clinical trial. Int Psychogeriatr 1997, 9:123.
4. Courtney C., Farrell D., Gray R., et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004, 363:2105.
5. Tariot P.N., Cummings J.L., Katz I.R., et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001, 49:1590.
6. Winblad B., Kilander L., Eriksson S., et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006, 367:1057.
7. Langa K.M., Foster N.L., Larson E.B. Mixed dementia: emerging concepts and therapeutic implications. JAMA 2004, 292:2901.
8. Grossberg G.T., Desai A.K. Management of Alzheimer's disease. J Gerontol A Biol Sci Med Sci 2003, 58:331.
9. Holmes C., Wilkinson D., Dean C., et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004, 63:214.
10. Rainer M., Mucke H.A., Kruger-Rainer C., et al. Cognitive relapse after discontinuation of drug therapy in Alzheimer's disease: cholinesterase inhibitors versus nootropics. J Neural Transm 2001, 108:1327.
11. Hernandez R.K., Farwell W., Cantor M.D., et al. Cholinesterase Inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs New England healthcare system. J Am Geriatr Soc 2009, 57(11):1997-2003.
12. Gill S.S., Anderson G.M., Fischer H.D., et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med 2009, 169:867.
13. Trinh N.H., Hoblyn J., Mohanty S., et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease. A meta-analysis. JAMA 2003, 289:210.
14. Schneider L.S. AD2000: donepezil in Alzheimer's disease. Lancet 2004, 363:2100.
15. Lopez O.L., Becker J.T., Wisniewski S., et al. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002, 72:310.
16. Sandson T.A. Metrifonate for Alzheimer's disease: is the next cholinesterase inhibitor better?. Neurology 1999, 52:675. [letter; comment].
17. Erkinjuntti T., Roman G., Gauthier S., et al. Emerging therapies for vascular dementia and vascular cognitive impairment. Stroke 2004, 35:1010.
18. McKeith I., Del Ser T., Spano P., et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000, 356:2031.
19. Reisberg B., Doody R., Stoffler A., et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003, 348:1333.
20. McShane R., Areosa Sastre A., Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006, 2. CD003154.
21. Tariot P.N., Farlow M.R., Grossberg G.T., et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004, 291:317.
22. Porsteinsson A.P., Grossberg G.T., Mintzer J., et al. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 2008, 5:83.
23. Day K., Carreon D., Stump C. The therapeutic design of environments for people with dementia: a review of the empirical research. Gerontologist 2000, 40(4):397-416.
24. O' Connor D., Phinney A., Smith A., et al. Personhood in dementia care: developing a research agenda for broadening the vision. Dementia 2007, 6(1):121-142.
25. Wahl H.W., Fange A., Oswald F., et al. Home environment and disability-related outcomes in aging individuals: what is the empirical evidence?. Gerontologist 2009, 49(3):355-367.
26. Van Hoof J., Kort H.S., van Waarde H., et al. Environmental interventions and the design of homes for older adults with dementia: an overview. Am J Alzheimers Dis Other Demen 2010, 25(3):202-232.
27. Kramer A.F., Bherer L., Colcombe S.J., et al. Environmental influences on cognitive and brain plasticity during aging. J Gerontol A Biol Sci Med Sci 2004, 59(9):940-957.
28. Kasl-Godley J., Gatz M. Psychosocial interventions for individuals with dementia: an integration of theory, therapy, m and a clinical understanding of dementia. Clin Psychol Rev 2000, 20(6):755-782.
29. Teresi J.A., Holmes D., Ory M.G. The therapeutic design of environments for people with dementia: further reflections and recent findings from the National Institute on Aging collaborative studies of dementia Special Care Units. Gerontologist 2000, 40(4):417-421.
30. Wood W., Harris S., Snider M., et al. Activity situations on an Alzheimer's disease special care unit and resident environmental interaction, time use, and affect. Am J Alzheimers Dis Other Demen 2005, 20(2):105-118.
31. Verbrugge L.M., Jette A.M. The disablement process. Soc Sci Med 1994, 38(1):1-14.
32. Marquardt G., Schmieg P. Dementia-friendly architecture: environments that facilitate wayfinding in nursing homes. Am J Alzheimers Dis Other Demen 2009, 24(4):333-340.
33. Brawley E. Alzheimer's disease: designing the physical environment. Am J Alzheimers Dis Other Demen 1992, 7(1):3-8.
34. Iwarsson S.A. Long-term perspective on person-environment fit and ADL dependence among older Swedish adults. Gerontologist 2005, 45(3):327-336.
35. Letts L., Law M., Rigby P., et al. Person-environment assessments in occupational therapy. Am J Occup Ther 1994, 48(7):608-618.
36. Iwarsson S., Horstmann V., Carlsson G., et al. Person-environment fit predicts falls in older adults better than the consideration of environmental hazards only. Clin Rehabil 2009, 23(6):558-567.
37. Wahl H.W., Oswarl D., Zimprich D. Everyday competence in visually impaired older adults: a case for person-environment perspectives. Gerontologist 1999, 39(2):140-149.
38. Kearns W.D., Fozard J.L. Technologies to manage wandering. Evidence-based protocols for managing wandering behaviors 2007, 277-297. Chapter 15, Springer Publishing Co, New York (NY). A.L. Nelson, D.L. Algase (Eds.).
39. Horvath K.J., Harvey R.M., Trudeau S.A. A home safety program for community based wanderers: outcomes from the Veterans Home Safety Project. Evidence-based protocols for managing wandering behaviors 2007, 259-276. Chapter 14, Springer Publishing Co, New York (NY). A.L. Nelson, D.L. Algase (Eds.).
40. Coste J.K. Learning to speak Alzheimer's 2003, Houghton Mifflin, New York (NY).
41. Hollinger L.M., Buschmann M.B. Factors influencing the perception of touch by elderly nursing home residents and their health caregivers. Int J Nurs Stud 1993, 30(5):445-461.
42. Burns A., Jacoby R., Levy R. Psychiatric phenomena in Alzheimer's disease: disorders of perception. Br J Psychiatry 1990, 157:76-81.
43. Eriksson S., Gustafson Y., Lundin-Olsson L. Characteristics associated with falls in patients with dementia in a psychogeriatric ward. Aging Clin Exp Res 2007, 19(2):97-103.
44. Shroyer J.L. Recommendations for environmental design research correlating falls and the physical environment. Exp Aging Res 1994, 20(4):303-309.
45. Ulfarsson J., Robinson B.E. Preventing falls and fractures. J Fla Med Assoc 1994, 81(11):763-767.
46. Zeilel J., Hyde J., Levkoff S. Best Practices: an environment-behavior model for Alzheimer special care units. Am J Alzheimers Dis Other Demen 1994, 9:4-21.
47. Connell B.R., Calkins M.P. Environmental design. Evidence-based protocols for managing wandering behaviors 2007, 301-336. Chapter 16, Springer Publishing Co, New York (NY). A.L. Nelson, D.L. Algase (Eds.).
48. Zuidema S., Koopmans R., Verhey F. Prevalence and predictors of neuropsychiatric symptoms in cognitively impaired nursing home patients. J Geriatr Psychiatry Neurol 2007, 20:41-49.
49. Seitz D., Purandare N., Conn D. Prevalence of psychiatric disorders among older adults in long-term care homes: a systematic review. Int Psychogeriatr 2010, 4:1-15.
50. Bartels S.J., Horn S.D., Smout R.J., et al. Agitation and depression in frail nursing home elderly patient with dementia-treatment characteristics and service use. Am J Geriatr Psychiatry 2003, 11:231-238.
51. Selboek G., Kirkevold Ø, Engedal K. The course of psychiatric and behavioral symptoms and the use of psychotropic medication in patients with dementia in Norwegian nursing homes-a 12 month follow-up study. Am J Geriatr Psychiatry 2008, 16:528-536.
52. Ballard C.G., Margallo-Lana M., Fossey J., et al. A 1-year follow-up study of behavioral and psychological symptoms in dementia among people in care environments. J Clin Psychiatry 2001, 62:631-636.
53. Zuidema S., Dersksen E., Verhey F., et al. Prevalence and neuropsychiatric symptoms in a large sample of Dutch nursing home patients with dementia. Int J Geriatr Psychiatry 2007, 22:632-638.
54. Wetzels R.B., Zuidema S.U., de Jonghe J.F., et al. Determinants of quality of life in nursing home residents with dementia. Dement Geriatr Cogn Disord 2010, 29:189-197.
55. Conn D., Thorpe L. Assessment of behavioural and psychological symptoms associated with dementia. Can J Neurol Sci 2007, 34(Suppl 1):S67-S71.
56. Snowden M., Sato K., Roy-Byrne P. Assessment and treatment of nursing home residents with depression or behavioral symptoms associated with dementia: a review of the literature. J Am Geriatr Soc 2003, 51:1305-1317.
57. American Geriatric Society and American Association Geriatric psychiatry Consensus statement on improving the quality of mental health care in U.S nursing homes: management of depression and behavioral symptoms associated with dementia. J Am Geriatr Soc 2003, 51(9):1287-1298.
58. Peskind E.R. Management of depression in long-term care of patients with Alzheimer's disease. J Am Med Dir Assoc 2003, 4(Suppl 6):S141-S145.
59. Magai C., Kennedy G., Cohen C.I., et al. A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer's disease. Am J Geriatr Psychiatry 2000, 8:66-74.
60. Williams C.L., Tappen R.M. Exercise training for depressed older adults with Alzheimer's disease. Aging Ment Health 2008, 12:72-80.
61. Street J.S., Clark S., Gannon K.S., et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities-a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2000, 57:968-976.
62. Tariot P.N., Erb R., Podgorski C.A., et al. Efficacy and tolerability of carmazepine for agitation and aggression in dementia. Am J Psychiatry 1998, 155:54-61.
63. Coccaro E.F., Kramer E., Zemishlany Z., et al. Pharmacologic treatment of noncognitive behavioral disturbances in elderly demented patients. Am J Psychiatry 1990, 147:1640-1645.
64. Testad I., Ballard C., Bronnick K., et al. The effect of staff training on agitation and use of restraint in nursing home residents with dementia: a single-blind, randomized controlled trial. J Clin Psychiatry 2010, 71:80-86.
65. Sloan P.D., Hoeffer B., Mitchell C.M., et al. Effect of person-centered showering and the towel bath on bathing-associated aggression, agitation, and discomfort in nursing home residents with dementia: a randomized, controlled trial. J Am Geriatr Soc 2004, 52:1795-1804.
66. McCallion P., Toseland R.W., Freeman K. An evaluation of a family visit education program. J Am Geriatr Soc 1999, 47:203-214.
67. Cohen-Mansfield J., Deutsch L.H. Agitation: subtype and their mechanisms. Semin Clin Neuropsychiatry 1996, 1:325-339.
68. Cohen-Mansfield J. Assessment of agitation. Int Psychogeriatr 1996, 8:233-245.
69. Sommer O.H., Kirkevold O., Cvancarova M., et al. Factor analysis of the brief agitation rating scale in a large sample of Norwegian nursing home patients. Dement Geriatr Cogn Disord 2010, 29:55-60.
70. Gerdner L.A. Evidence-based guideline: individualized music for elders with dementia. J Gerontol Nurs 2000, 36:7-15.
71. Gehrman P.R., Martin J.L., Shochat T., et al. Sleep-disordered breathing and agitation in institutionalized adults with Alzheimer disease. Am J Geriatr Psychiatry 2003, 11:426-433.
72. Menon A.S., Gruber-Baldini A.L., Hebel J.R., et al. Relationship between aggressive behaviors and depression among nursing home residents with dementia. Int J Geriatr Psychiatry 2001, 16:139-146.
73. Cohen-Mansfield J., Billig N., Lipson S., et al. Medical correlates of agitation in nursing home residents. Gerontology 1990, 36:150-158.
74. Sloan P.D., Mitchell C.M., Preisser J.S., et al. Environmental correlates of resident agitation in Alzheimer's disease special care units. J Am Geriatr Soc 1998, 46:862-869.
75. Tariot P.N., Raman R., Jakimovich L., et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. Am J Geriatr Psychiatry 2005, 13:942-949.
76. Finkel S.I., Lyons J.S., Anderson R.L., et al. A randomized, placebo-controlled trial of thiothixene in agitated, demented nursing home patients. Int J Geriatr Psychiatry 1995, 10:129-136.
77. Cohen-Mansfield J., Marx M.S., Dakbeel-Ali M., et al. Can agitated behavior of nursing home residents with dementia be prevented with standardized stimuli?. J Am Geriatr Soc 2010, 58:1459-1464.
78. Burns A., Allen H., Tomenson B., et al. Bright light therapy for agitation in dementia: a randomized controlled trial. Int Psychogeriatr 2009, 21:711-721.
79. Wan-ki Lin P., Chan W.C., Fung-leung Ng B., et al. Efficacy of aromatherapy (Lavandula angustifolia) as an intervention for agitated behaviors in Chinese older persons with dementia: a cross-over randomized trial. Int J Geriatr Psychiatry 2007, 22:405-410.
80. Cohen-Mansfield J., Libin A., Mark M.S. Nonpharmacological treatment of agitation: a controlled trial of systematic individualized intervention. J Gerontol A Biol Sci Med Sci 2007, 62A:908-916.
81. Garland K., Beer E., Eppingstall B., et al. A comparison of two treatments of agitated behaviors in nursing home residents with dementia: simulated family presence and preferred music. Am J Geriatr Psychiatry 2007, 15:514-521.
82. Sung H.C., Chang S.M., Lee W.L., et al. The effects of group music movement intervention on agitated behaviours of institutionalized elders with dementia in Taiwan. Complement Ther Med 2006, 14:113-119.
83. Ancoli-Israel S., Martin J.L., Gebrman P., et al. Effect of light on agitation in institutionalized patients with severe Alzheimer disease. Am J Geriatr Psychiatry 2003, 11:194-203.
84. Ballard C.G., O'Brien J.T., Reichelt K., et al. Aromatherapy as a safe and effective treatment for the management of agitation in server dementia: the results of a double-blind, placebo-controlled trial with Melissa. J Clin Psychiatry 2002, 63:553-558.
85. Remington R. Calming music and hand massage with agitated elderly. Nurs Res 2002, 51:317-323.
86. Gerdner L.A. Effects of individualized versus classical " relaxation" music on the frequency of agitation in elderly persons with Alzheimer's disease and related disorders. Int Psychogeriatr 2000, 12:49-65.
87. Lyketsos C.G., Veiel L.L., Baker A., et al. A randomized, controlled trial of bright light therapy for agitated behaviors in dementia patients residing in long-term care. Int J Geriatr Psychiatry 1999, 14:520-525.
88. Closs S.J., Barr B., Briggs M. Cognitive status and analgesic provision in nursing home residents. Br J Gen Pract 2004, 54:919-921.
89. Nagaard H.A., Jarland M. Are nursing home patients with dementia diagnosis at increased risk for inadequate pain treatment?. Int J Geriatr Psychiatry 2005, 20:730-737.
90. Locca J.F., Bula C.J., Zumbach S., et al. Pharmacological treatment of behavioral and psychological symptoms of dementia (BPSD) in nursing homes: development of practice recommendations in a Swiss canton. J Am Med Dir Assoc 2008, 9:439-448.
91. Class C.A., Schneiderder L., Farlow M.R. Optimal management of behavioral disorders associated with dementia. Drugs Aging 1997, 10:95-106.
92. Cohen-Mansfield J. Nonpharmacologic interventions for inappropriate behaviors in dementia. J Geriatr Psychiatry Neurol 2001, 9:361-381.
93. Cohen-Mansfield J. Nonpharmacologic interventions for psychotic symptoms in dementia. J Geriatr Psychiatry Neurol 2003, 16:219-224.
94. Bharani N., Snowden M. Evidence-based interventions for nursing home residents with dementia-related behavioral symptoms. Psychiatr Clin North Am 2005, 28:985-1005.
95. De Deyn P.P., Katz I.R., rodaty H., et al. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone. Clin Neurol Neurosurg 2005, 107:497-508.
96. Ayalon L., Gum A.M., Feliciano L., et al. Effectiveness of nonpharmacological interventions for the management of neuropsychiatric symptoms in patients with dementia: a systematic review. Arch Intern Med 2006, 166:2182-2188.
97. Daiello L.A. Atypical antipsychotics for the treatment of dementia-related behaviors: an update. Med Health R I 2007, 90:191-194.
98. Rodda J., Morgan S., Walker Z. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int Psychogeriatr 2009, 21:813-824.
99. Lai C.K., Yeung J.H., Mok V., et al. Special care units for dementia individuals with behavioral problems. Cochrane Database Syst Rev 2009, 4. 10.1002/14651858.CD006470.pub2.
100. Li I. Feeding tubes in patients with severe dementia. Am Fam Physician 2002, 65(8):1605-1610.
101. Robertson R.G., Montagnini M. Geriatric failure to thrive. Am Fam Physician 2004, 70(2):343-350.
102. Mitchell S.L., Teno J.M., Kiely D.K., et al. The clinical course of advanced dementia. N Engl J Med 2009, 361:1529-1538.
103. Rehman H.U. Involuntary weight loss in the elderly. Clin Geriatr 2005, 13(7):37-47.
104. Farrell T., Tuya A. Nutrition in the older adult. Med Health R I 2008, 91(2):65-66.
105. Yeh S., Wu S.Y., Levine D.M., et al. Quality of life and stimulation of weight gain after treatment with megestrol acetate: correlation between cytokine levels and nutritional status, appetite in geriatric patients with wasting syndrome. J Nutr Health Aging 2000, 4(4):246-251.
106. Reuben D.B., Hirsch S.H., Zhou K., et al. The effects of megestrol acetate suspension for elderly patients with reduced appetite after hospitalization: a phase II randomized clinical trial. J Am Geriatr Soc 2005, 53(6):970-975.